FDA Committee to Discuss Regulation of Popular Peptides This Week

Want the full story?
Read the complete article at KVIA
AI Summary
A little-known advisory group from the U.S. Food and Drug Administration (FDA) is set to meet this week to consider easing restrictions on certain injectable peptides, which have gained popularity among wellness influencers and some medical professionals. The meeting, scheduled for Thursday and Friday, will evaluate seven proposed peptides for inclusion in the FDA's '503A Bulks' list, allowing compounding pharmacies to prepare them. However, FDA experts have indicated that there is insufficient evidence regarding the safety and efficacy of these peptides, which are currently unapproved. The outcome of this meeting could significantly impact how these substances are regulated and accessed by the public, particularly for those purchasing them online without medical guidance.
Key Details: • Meeting scheduled for Thursday and Friday to discuss peptide regulations. • Seven peptides under review include BPC-157 and TB-500. • FDA experts recommend against including these peptides in the '503A Bulks' list. • Public concerns about safety and efficacy of unapproved peptides persist.